HARROW, INC.

Harrow, Inc. reported second-quarter 2026 revenue of $70.7 million, a 60% sequential increase and 11% year-over-year growth. Despite a net loss of $17.3 million and negative Adjusted EBITDA, the company reiterated its full-year 2026 revenue guidance of $350 million to $365 million and Adjusted EBITDA of $80 million to $100 million. Key drivers included strong performance from VEVYE, IHEEZO, and TRIESENCE, the launch of BYOOVIZ, and the announced acquisition of TYRVAYA, positioning the company for accelerated growth in the second half of 2026.

Harrow, Inc. has entered into an Asset Purchase Agreement with Viatris Inc. to acquire the global rights to TYRVAYA® (varenicline solution) nasal spray, an FDA-approved treatment for dry eye disease. The acquisition involves an upfront cash payment of $30 million, with potential contingent milestone payments of up to an additional $70 million based on net sales, totaling up to $100 million. This strategic move expands Harrow's dry eye portfolio, complementing its VEVYE franchise by offering a differentiated treatment option and leveraging existing commercial infrastructure. The upfront payment will be funded with cash on hand, and the transaction is expected to close in the second half of 2026.

Harrow, Inc. announced a definitive agreement to acquire TYRVAYA® (varenicline solution) nasal spray from Viatris Inc. for an upfront cash payment of $30 million and up to $70 million in contingent milestone payments, totaling up to $100 million. This acquisition significantly expands Harrow's dry eye portfolio, complementing its VEVYE franchise by offering a differentiated treatment option. The company expects to fund the upfront payment with cash on hand, with the transaction anticipated to close in the second half of 2026.

Harrow, Inc. announced it will release its financial results for the second quarter ended June 30, 2026, on Monday, August 10, 2026, after the market closes. The company will also host a conference call and live webcast to discuss the results and provide a business update on Tuesday, August 11, 2026, at 8:00 a.m. Eastern Time. A Letter to Stockholders will be posted on the company's investor relations website.

Harrow and Samsung Bioepis presented interim data from a post-marketing surveillance (PMS) study for SB11 (BYOOVIZ® / AMELIVU®), a biosimilar referencing Lucentis, at the ASRS 44th Annual Meeting. The study demonstrated a comparable safety profile of SB11 to reference ranibizumab. It also showed clinically meaningful efficacy improvement in treatment-naïve patients and maintained efficacy in those switched from other anti-VEGF therapies, reinforcing confidence in the biosimilar.

Harrow announced the presentation of three studies supporting IHEEZO and BYOOVIZ at the American Society of Retina Specialists (ASRS) 2026 Annual Meeting. Interim findings for IHEEZO showed encouraging trends toward less post-procedure pain and a better patient experience, with topline data from the larger QUELL study expected in Q4 2026. A real-world study for IHEEZO also found no increased endophthalmitis risk across nearly 20,000 injections, while Samsung Bioepis presented interim BYOOVIZ post-marketing surveillance data. These presentations expand the clinical and real-world evidence for Harrow's retina portfolio, reinforcing physician confidence and supporting product adoption.

Harrow, Inc. announced the commercial launch of BYOOVIZ® (ranibizumab-nuna), an FDA-approved biosimilar developed by Samsung Bioepis. This launch follows an exclusive U.S. commercialization agreement, positioning BYOOVIZ as the first ophthalmology biosimilar in the U.S. for conditions like Wet Age-Related Macular Degeneration. The product is an interchangeable biosimilar to LUCENTIS® and is expected to significantly strengthen Harrow's retina franchise in the estimated $9 billion U.S. anti-VEGF market, alongside its existing products IHEEZO® and TRIESENCE®.

Harrow, Inc. announced the re-launch of VERKAZIA® (cyclosporine ophthalmic emulsion) 0.1%, a prescription therapy for vernal keratoconjunctivitis (VKC), a serious allergic eye disease affecting children. This steroid-sparing treatment targets underlying inflammatory mechanisms, aiming to provide consistent access and reduce reliance on corticosteroids, which carry significant risks. The re-launch is supported by a comprehensive commercial strategy focused on physician education, patient access, and affordability.

Harrow, Inc. has released its corporate presentation, dated June 2026, which will be used by the company's management. This presentation is intended for use at investor conferences and in meetings with investors, analysts, and other interested parties. The information was furnished under Regulation FD Disclosure.

Harrow, Inc. announced that its management will present at William Blair's 46th Annual Growth Stock Conference on Wednesday, June 3, 2026, at 8:40 AM CT in Chicago, IL. The presentation will be webcast live on the company's website, with a replay available for about 90 days following the event.